WebNov 24, 2024 · Biogen reported third-quarter 2024 adjusted earnings per share (EPS) of $4.77, beating the Zacks Consensus Estimate of $4.13 and our model estimate of $4.30. Earnings were flat year over year Sales came in at $2.51 billion, down 10% on a reported basis (8% on a constant-currency basis) from the year-ago quarter, hurt by lower sales of … WebFind the latest Earnings Report Date for Biogen Inc. Common Stock (BIIB) at Nasdaq.com.
2024-04-12 NDAQ:BIIB Press Release Biogen Inc.
WebFeb 15, 2024 · SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States CAMBRIDGE, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug … WebOct 20, 2024 · Additional information regarding the GAAP and Non-GAAP financial measures and a reconciliation of the GAAP to Non-GAAP financial measures can be found on slides 39-42 of this presentation and in the Q3 2024 earnings release and related financial tables posted on the Investors section of Biogen.com. We believe that these … optic tracts/nerve function
BIIB: Biogen - Detailed Earnings Estimates - Zacks.com
WebJul 20, 2024 · Biogen Reports Second Quarter 2024 Results. Second quarter revenue $2,589 million; GAAP diluted EPS $7.24; Non-GAAP diluted EPS $5.25. FDA granted Priority Review for lecanemab in early Alzheimer's disease under the accelerated approval pathway with a decision expected by January 6, 2024; Phase 3 data expected in the Fall … Web2 days ago · Look out for BIIB's next earnings release expected on May 02, 2024. For the next earning release, we expect the company to report earnings of $3.32 per share, … WebApr 19, 2024 · For the last reported quarter, Biogen Inc. Came out with earnings of $3.39 per share versus the Zacks Consensus Estimate of $3.32 per share, representing a surprise of 2.11%. For the previous ... optic tracts function